Conclusions and Recommendations Key messages for at-risk populations: The EVOKE trial failure does not invalidate GLP-1 agonists for preventionthe epidemiological signal remains strong, and these drugs may provide metabolic and cardiovascular benefits with potential cognitive co-benefits when used for approved indications SS-31s approval establishes precedent for mitochondrial-targeted therapeuticswatch this space for expanded indications Popular biohacker peptides (BPC-157, Dihexa, P21) have essentially no human cognitive evidence
Naturally produced in the liver, this powerful tripeptide (composed of three amino acids: glutamine, cysteine, and glycine) plays a crucial role in detoxification, cellular repair, and immune function
Bibcode:1998BBRC..250..506V
Vi nhng ai cha bit, t bo m ni chung v cht bo ni ring l mi trng d tr ATP ln nht ca c th, ng thi c th chng ta s dng ATP l ngun nng lng chnh vn ng hng ngy
IGF1 has a smaller chain with 70 amino acids, and the IGF1 LR3 has 83 amino acids
It is not FDA-approved, is not a weight-loss medication, and any use should be discussed with a qualified prescriber
